Does the media prefer IONS or ZLAB?

In the previous week, Ionis Pharmaceuticals had 22 more articles in the media than Zai Lab. MarketBeat recorded 26 mentions for Ionis Pharmaceuticals and 4 mentions for Zai Lab. Ionis Pharmaceuticals' average media sentiment score of 1.18 beat Zai Lab's score of 0.34 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 17 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Zai Lab 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PRAX or ZLAB?

In the previous week, Praxis Precision Medicines and Praxis Precision Medicines both had 4 articles in the media. Praxis Precision Medicines' average media sentiment score of 1.02 beat Zai Lab's score of 0.34 indicating that Praxis Precision Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Praxis Precision Medicines 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ZLAB or SMMT more profitable?

Summit Therapeutics has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Zai Lab -41.86% -27.43% -16.72% Summit Therapeutics N/A -168.94% -141.92%

Does the media favor ZLAB or SMMT?

In the previous week, Summit Therapeutics had 12 more articles in the media than Zai Lab. MarketBeat recorded 16 mentions for Summit Therapeutics and 4 mentions for Zai Lab. Summit Therapeutics' average media sentiment score of 0.62 beat Zai Lab's score of 0.34 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zai Lab 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Summit Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has preferable valuation and earnings, ABVX or ZLAB?

Zai Lab has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Zai Lab $460.16M 6.68 -$175.54M -$1.71 N/A

Is ABVX or ZLAB more profitable?

Abivax has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Zai Lab -41.86% -27.43% -16.72%

Does the media refer more to ABVX or ZLAB?

In the previous week, Zai Lab had 3 more articles in the media than Abivax. MarketBeat recorded 4 mentions for Zai Lab and 1 mentions for Abivax. Abivax's average media sentiment score of 1.19 beat Zai Lab's score of 0.34 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, KRYS or ZLAB?

Krystal Biotech has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Krystal Biotech $389.13M 28.26 $204.83M $7.98 46.55 Zai Lab $460.16M 6.68 -$175.54M -$1.71 N/A

Is KRYS or ZLAB more profitable?

Krystal Biotech has a net margin of 54.82% compared to Zai Lab's net margin of -41.86%. Krystal Biotech's return on equity of 19.34% beat Zai Lab's return on equity. Company Net Margins Return on Equity Return on Assets Krystal Biotech 54.82% 19.34% 17.65% Zai Lab -41.86% -27.43% -16.72%

Does the media favor KRYS or ZLAB?

In the previous week, Krystal Biotech had 5 more articles in the media than Zai Lab. MarketBeat recorded 9 mentions for Krystal Biotech and 4 mentions for Zai Lab. Krystal Biotech's average media sentiment score of 1.52 beat Zai Lab's score of 0.34 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Zai Lab 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Zai Lab (ZLAB) Competitors

$27.00 +0.52 (+1.96%)

As of 09/3/2026 04:00 PM Eastern

Compare

ZLAB vs. IONS, PRAX, SMMT, ABVX, and KRYS

Should you buy Zai Lab stock or one of its competitors? Zai Lab's main competitors and comparable companies include Ionis Pharmaceuticals (IONS), Praxis Precision Medicines (PRAX), Summit Therapeutics (SMMT), Abivax (ABVX), and Krystal Biotech (KRYS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Zai Lab compare to Ionis Pharmaceuticals?

Ionis Pharmaceuticals (NASDAQ:IONS) and Zai Lab (NASDAQ:ZLAB) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

Ionis Pharmaceuticals has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, Zai Lab has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market.

In the previous week, Ionis Pharmaceuticals had 22 more articles in the media than Zai Lab. MarketBeat recorded 26 mentions for Ionis Pharmaceuticals and 4 mentions for Zai Lab. Ionis Pharmaceuticals' average media sentiment score of 1.18 beat Zai Lab's score of 0.34 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	17 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Zai Lab	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 1.8% of Ionis Pharmaceuticals shares are owned by company insiders. Comparatively, 4.9% of Zai Lab shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Zai Lab has a net margin of -41.86% compared to Ionis Pharmaceuticals' net margin of -64.76%. Zai Lab's return on equity of -27.43% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%
Zai Lab	-41.86%	-27.43%	-16.72%

Ionis Pharmaceuticals currently has a consensus target price of $94.15, suggesting a potential upside of 61.96%. Zai Lab has a consensus target price of $37.25, suggesting a potential upside of 37.96%. Given Ionis Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Ionis Pharmaceuticals is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Zai Lab has lower revenue, but higher earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	10.23	-$381.39M	-$3.46	N/A
Zai Lab	$460.16M	6.68	-$175.54M	-$1.71	N/A

Summary

Zai Lab beats Ionis Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Zai Lab compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Zai Lab (NASDAQ:ZLAB) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Zai Lab has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Praxis Precision Medicines	$8.55M	1,159.74	-$303.27M	-$12.93	N/A
Zai Lab	$460.16M	6.68	-$175.54M	-$1.71	N/A

Praxis Precision Medicines has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Praxis Precision Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Praxis Precision Medicines	N/A	-34.15%	-32.42%
Zai Lab	-41.86%	-27.43%	-16.72%

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by company insiders. Comparatively, 4.9% of Zai Lab shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Praxis Precision Medicines and Praxis Precision Medicines both had 4 articles in the media. Praxis Precision Medicines' average media sentiment score of 1.02 beat Zai Lab's score of 0.34 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Praxis Precision Medicines	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Praxis Precision Medicines has a beta of 2.76, meaning that its stock price is 176% more volatile than the broader market. Comparatively, Zai Lab has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

Praxis Precision Medicines currently has a consensus price target of $585.95, suggesting a potential upside of 64.99%. Zai Lab has a consensus price target of $37.25, suggesting a potential upside of 37.96%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts clearly believe Praxis Precision Medicines is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Praxis Precision Medicines	2 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.95
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Praxis Precision Medicines beats Zai Lab on 9 of the 16 factors compared between the two stocks.

How does Zai Lab compare to Summit Therapeutics?

Zai Lab (NASDAQ:ZLAB) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

In the previous week, Summit Therapeutics had 12 more articles in the media than Zai Lab. MarketBeat recorded 16 mentions for Summit Therapeutics and 4 mentions for Zai Lab. Summit Therapeutics' average media sentiment score of 0.62 beat Zai Lab's score of 0.34 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zai Lab	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Summit Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

41.7% of Zai Lab shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 4.9% of Zai Lab shares are owned by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Zai Lab presently has a consensus price target of $37.25, indicating a potential upside of 37.96%. Summit Therapeutics has a consensus price target of $24.07, indicating a potential upside of 40.53%. Given Summit Therapeutics' higher probable upside, analysts plainly believe Summit Therapeutics is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.44

Zai Lab has higher revenue and earnings than Summit Therapeutics. Zai Lab is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zai Lab	$460.16M	6.68	-$175.54M	-$1.71	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

Zai Lab has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.24, suggesting that its stock price is 224% less volatile than the broader market.

Summit Therapeutics has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zai Lab	-41.86%	-27.43%	-16.72%
Summit Therapeutics	N/A	-168.94%	-141.92%

Summary

Summit Therapeutics beats Zai Lab on 8 of the 15 factors compared between the two stocks.

How does Zai Lab compare to Abivax?

Abivax (NASDAQ:ABVX) and Zai Lab (NASDAQ:ZLAB) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

In the previous week, Zai Lab had 3 more articles in the media than Abivax. MarketBeat recorded 4 mentions for Zai Lab and 1 mentions for Abivax. Abivax's average media sentiment score of 1.19 beat Zai Lab's score of 0.34 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zai Lab has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Zai Lab	$460.16M	6.68	-$175.54M	-$1.71	N/A

Abivax presently has a consensus price target of $156.50, indicating a potential upside of 37.23%. Zai Lab has a consensus price target of $37.25, indicating a potential upside of 37.96%. Given Zai Lab's higher possible upside, analysts plainly believe Zai Lab is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

47.9% of Abivax shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 4.9% of Zai Lab shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Abivax has a net margin of 0.00% compared to Zai Lab's net margin of -41.86%. Zai Lab's return on equity of -27.43% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Zai Lab	-41.86%	-27.43%	-16.72%

Abivax has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Zai Lab has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

Summary

Zai Lab beats Abivax on 10 of the 16 factors compared between the two stocks.

How does Zai Lab compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Zai Lab (NASDAQ:ZLAB) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

In the previous week, Krystal Biotech had 5 more articles in the media than Zai Lab. MarketBeat recorded 9 mentions for Krystal Biotech and 4 mentions for Zai Lab. Krystal Biotech's average media sentiment score of 1.52 beat Zai Lab's score of 0.34 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Zai Lab	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Krystal Biotech currently has a consensus target price of $365.40, indicating a potential downside of 1.63%. Zai Lab has a consensus target price of $37.25, indicating a potential upside of 37.96%. Given Zai Lab's higher probable upside, analysts plainly believe Zai Lab is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Krystal Biotech has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	28.26	$204.83M	$7.98	46.55
Zai Lab	$460.16M	6.68	-$175.54M	-$1.71	N/A

86.3% of Krystal Biotech shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by insiders. Comparatively, 4.9% of Zai Lab shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Krystal Biotech has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Zai Lab has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

Krystal Biotech has a net margin of 54.82% compared to Zai Lab's net margin of -41.86%. Krystal Biotech's return on equity of 19.34% beat Zai Lab's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
Zai Lab	-41.86%	-27.43%	-16.72%

Summary

Krystal Biotech beats Zai Lab on 13 of the 16 factors compared between the two stocks.

Get Zai Lab News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZLAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZLAB vs. The Competition

Export

Metric	Zai Lab	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.01B	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-15.79	12.66	273.29	25.38
Price / Sales	6.68	1,309.08	613.45	92.55
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	5.06	16.29	12.89	6.14
Net Income	-$175.54M	-$22.72M	$3.47B	$349.01M
7 Day Performance	3.53%	0.34%	0.60%	-0.27%
1 Month Performance	46.02%	8.52%	5.73%	0.68%
1 Year Performance	-10.00%	52.66%	25.35%	14.84%

Zai Lab Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZLAB Zai Lab	2.5634 of 5 stars	$27.00 +2.0%	$37.25 +38.0%	-13.7%	$3.01B	$460.16M	N/A	1,784
IONS Ionis Pharmaceuticals	3.7346 of 5 stars	$63.57 +2.5%	$94.15 +48.1%	-3.9%	$10.31B	$944M	N/A	1,402	Positive News
PRAX Praxis Precision Medicines	3.175 of 5 stars	$368.02 0.0%	$585.95 +59.2%	+662.9%	$10.28B	$8.55M	N/A	110	Positive News
SMMT Summit Therapeutics	3.4991 of 5 stars	$13.36 +4.9%	$24.07 +80.2%	-27.2%	$10.16B	N/A	N/A	110	Analyst Forecast Gap Up
ABVX Abivax	2.5152 of 5 stars	$117.93 +1.5%	$156.50 +32.7%	+36.3%	$10.13B	N/A	N/A	61	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZLAB) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zai Lab (ZLAB) Competitors

ZLAB vs. IONS, PRAX, SMMT, ABVX, and KRYS

How does Zai Lab compare to Ionis Pharmaceuticals?

Summary

How does Zai Lab compare to Praxis Precision Medicines?

Summary

How does Zai Lab compare to Summit Therapeutics?

Summary

How does Zai Lab compare to Abivax?

Summary

How does Zai Lab compare to Krystal Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZLAB vs. The Competition

Zai Lab Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zai Lab (ZLAB) Competitors

ZLAB vs. IONS, PRAX, SMMT, ABVX, and KRYS

How does Zai Lab compare to Ionis Pharmaceuticals?

Which has more risk and volatility, IONS or ZLAB?

Does the media prefer IONS or ZLAB?

Do institutionals and insiders have more ownership in IONS or ZLAB?

Is IONS or ZLAB more profitable?

Do analysts recommend IONS or ZLAB?

Which has preferable valuation and earnings, IONS or ZLAB?

Summary

How does Zai Lab compare to Praxis Precision Medicines?

Which has stronger valuation & earnings, PRAX or ZLAB?

Is PRAX or ZLAB more profitable?

Do institutionals and insiders hold more shares of PRAX or ZLAB?

Does the media prefer PRAX or ZLAB?

Which has more volatility and risk, PRAX or ZLAB?

Do analysts rate PRAX or ZLAB?

Summary

How does Zai Lab compare to Summit Therapeutics?

Does the media favor ZLAB or SMMT?

Do insiders & institutionals believe in ZLAB or SMMT?

Do analysts rate ZLAB or SMMT?

Which has stronger earnings & valuation, ZLAB or SMMT?

Which has more risk and volatility, ZLAB or SMMT?

Is ZLAB or SMMT more profitable?

Summary

How does Zai Lab compare to Abivax?

Does the media refer more to ABVX or ZLAB?

Which has preferable valuation and earnings, ABVX or ZLAB?

Do analysts rate ABVX or ZLAB?

Do institutionals & insiders believe in ABVX or ZLAB?

Is ABVX or ZLAB more profitable?

Which has more volatility & risk, ABVX or ZLAB?

Summary

How does Zai Lab compare to Krystal Biotech?

Does the media favor KRYS or ZLAB?

Do analysts prefer KRYS or ZLAB?

Which has preferable valuation & earnings, KRYS or ZLAB?

Do institutionals and insiders hold more shares of KRYS or ZLAB?

Which has more risk & volatility, KRYS or ZLAB?

Is KRYS or ZLAB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZLAB vs. The Competition

Zai Lab Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools